Amyotrophic Lateral Sclerosis(ALS) Clinical Trials

12 recruiting

Frequently Asked Questions

Common questions about Amyotrophic Lateral Sclerosis(ALS) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 2

Study of COYA 302 for the Treatment of ALS

Amyotrophic Lateral Sclerosis(ALS)
Coya Therapeutics120 enrolled24 locationsNCT07161999
Recruiting
Phase 1Phase 2

First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Amyotrophic Lateral Sclerosis(ALS)Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Regeneron Pharmaceuticals42 enrolled16 locationsNCT06351592
Recruiting

Retinal Imaging in Neurodegenerative Disease

Traumatic Brain InjuryHuntington DiseaseNeuro-Degenerative Disease+12 more
Duke University2,000 enrolled1 locationNCT03233646
Recruiting
Phase 2

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

Amyotrophic Lateral Sclerosis(ALS)
PhenoNet, Inc.105 enrolled12 locationsNCT07142291
Recruiting
Not Applicable

Quantification of Hsp90 in the Human Brain

Amyotrophic Lateral Sclerosis(ALS)Alzheimer's Disease(AD)Parkinson's Disease (PD)
Universitaire Ziekenhuizen KU Leuven48 enrolled1 locationNCT07380204
Recruiting

UPenn Observational Research Repository on Neurodegenerative Disease

Corticobasal Syndrome(CBS)Progressive Supranuclear Palsy (PSP)Primary Progressive Aphasia(PPA)+6 more
University of Pennsylvania1,000 enrolled1 locationNCT04715399
Recruiting

Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging

EpilepsyMultiple SclerosisAlzheimer Disease+7 more
Assistance Publique Hopitaux De Marseille700 enrolled1 locationNCT07202494
Recruiting
Phase 1

Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis(ALS)
Novabio Therapeutics12 enrolled1 locationNCT06671236
Recruiting
Phase 1Phase 2

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

Amyotrophic Lateral Sclerosis(ALS)Alzheimer Disease (AD)Parkinson Disease (PD)+1 more
Ashvattha Therapeutics, Inc.65 enrolled3 locationsNCT05395624
Recruiting
Early Phase 1

[18F]ACI-19626 PET in TDP-43 Proteinopathies

Amyotrophic Lateral Sclerosis(ALS)Alzheimer's Disease(AD)Frontotemporal Dementia (FTD)+2 more
AC Immune SA45 enrolled1 locationNCT06891716
Recruiting

Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders

Parkinson DiseaseAmyotrophic Lateral Sclerosis(ALS)Alzheimer&Amp;#39;s Disease (AD)+1 more
Neuromed IRCCS110 enrolled1 locationNCT06803784
Recruiting
Phase 1

A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418

Amyotrophic Lateral Sclerosis(ALS)Parkinson Disease Psychosis
1ST Biotherapeutics, Inc.64 enrolled1 locationNCT05995782